Zobraziť v EDS

Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy.

Uložené v:
Podrobná bibliografia
Názov: Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy.
Autori: Rohrbach, J., Robinson, N., Harcourt, G., Hammond, E., Gaudieri, S., Gorgievski, M., Telenti, A., Keiser, O., Günthard, H.F., Hirschel, B., Hoffmann, M., Bernasconi, E., Battegay, M., Furrer, H., Klenerman, P., Rauch, A.
Prispievatelia: Swiss HIV Cohort Study, Battegay, M., Bernasconi, E., Böni, J., Bucher, HC., Bürgisser, P., Calmy, A., Cattacin, S., Cavassini, M., Dubs, R., Egger, M., Elzi, L., Erb, P., Fischer, M., Flepp, M., Fontana, A., Francioli, P., Furrer, H., Fux, C., Gorgievski, M., Günthard, H., Hirsch, H., Hirschel, B., Hösli, I., Kahlert, Ch., Kaiser, L., Karrer, U., Kind, C., Klimkait, T., Ledergerber, B., Martinetti, G., Martinez, B., Müller, N., Nadal, D., Opravil, M., Paccaud, F., Pantaleo, G., Rauch, A., Regenass, S., Rickenbach, M., Rudin, C., Schmid, P., Schultze, D., Schüpbach, J., Speck, P., Taffé, P., Tarr, P., Telenti, A., Trkola, A., Vernazza, P., Weber, R., Yerly, S.
Rok vydania: 2025
Zbierka: Université de Lausanne (UNIL): Serval - Serveur académique lausannois
Predmety: Adult, Anti-HIV Agents/therapeutic use, Antiretroviral Therapy, Highly Active, CD4 Lymphocyte Count, Cohort Studies, Female, HIV Infections/complications, HIV Infections/drug therapy, Hepacivirus/drug effects, Hepacivirus/genetics, Hepatitis C Antigens/immunology, Hepatitis C, Chronic/complications, Chronic/drug therapy, Humans, Immunity, Cellular/drug effects, Interferon-gamma/biosynthesis, Longitudinal Studies, Male, RNA, Viral/blood, T-Lymphocytes/drug effects, T-Lymphocytes/immunology, Viral Core Proteins/immunology, Viral Load/drug effects
Popis: BACKGROUND: Hepatitis C virus (HCV) infection is a major cause of morbidity in HIV infected individuals. Coinfection with HIV is associated with diminished HCV-specific immune responses and higher HCV RNA levels. AIMS: To investigate whether long-term combination antiretroviral therapy (cART) restores HCV-specific T cell responses and improves the control of HCV replication. METHODS: T cell responses were evaluated longitudinally in 80 HIV/HCV coinfected individuals by ex vivo interferon-gamma-ELISpot responses to HCV core peptides, that predominantly stimulate CD4(+) T cells. HCV RNA levels were assessed by real-time PCR in 114 individuals. RESULTS: The proportion of individuals with detectable T cell responses to HCV core peptides was 19% before starting cART, 24% in the first year on cART and increased significantly to 45% and 49% after 33 and 70 months on cART (p=0.001). HCV-specific immune responses increased in individuals with chronic (+31%) and spontaneously cleared HCV infection (+30%). Median HCV RNA levels before starting cART were 6.5 log(10) IU/ml. During long-term cART, median HCV-RNA levels slightly decreased compared to pre-cART levels (-0.3 log10 IU/ml, p=0.02). CONCLUSIONS: Successful cART is associated with increasing cellular immune responses to HCV core peptides and with a slight long-term decrease in HCV RNA levels. These findings are in line with the favourable clinical effects of cART on the natural history of hepatitis C and with the current recommendation to start cART earlier in HCV/HIV coinfected individuals.
Druh dokumentu: article in journal/newspaper
Jazyk: English
ISSN: 1468-3288
Relation: Gut; https://iris.unil.ch/handle/iris/64704; serval:BIB_1B5145FB1283; 000282187100020
DOI: 10.1136/gut.2009.205971
Dostupnosť: https://iris.unil.ch/handle/iris/64704
https://doi.org/10.1136/gut.2009.205971
Prístupové číslo: edsbas.A00EB54F
Databáza: BASE
Popis
Abstrakt:BACKGROUND: Hepatitis C virus (HCV) infection is a major cause of morbidity in HIV infected individuals. Coinfection with HIV is associated with diminished HCV-specific immune responses and higher HCV RNA levels. AIMS: To investigate whether long-term combination antiretroviral therapy (cART) restores HCV-specific T cell responses and improves the control of HCV replication. METHODS: T cell responses were evaluated longitudinally in 80 HIV/HCV coinfected individuals by ex vivo interferon-gamma-ELISpot responses to HCV core peptides, that predominantly stimulate CD4(+) T cells. HCV RNA levels were assessed by real-time PCR in 114 individuals. RESULTS: The proportion of individuals with detectable T cell responses to HCV core peptides was 19% before starting cART, 24% in the first year on cART and increased significantly to 45% and 49% after 33 and 70 months on cART (p=0.001). HCV-specific immune responses increased in individuals with chronic (+31%) and spontaneously cleared HCV infection (+30%). Median HCV RNA levels before starting cART were 6.5 log(10) IU/ml. During long-term cART, median HCV-RNA levels slightly decreased compared to pre-cART levels (-0.3 log10 IU/ml, p=0.02). CONCLUSIONS: Successful cART is associated with increasing cellular immune responses to HCV core peptides and with a slight long-term decrease in HCV RNA levels. These findings are in line with the favourable clinical effects of cART on the natural history of hepatitis C and with the current recommendation to start cART earlier in HCV/HIV coinfected individuals.
ISSN:14683288
DOI:10.1136/gut.2009.205971